Opportunity Information: Apply for PAR 13 115
Apply for PAR 13 115
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121 Oral Diseases and Disorders Research 93.351 Research Infrastructure Programs 93.837 Cardiovascular Diseases Research 93.846 Arthritis, Musculoskeletal and Skin Diseases Research.
- This funding opportunity was created on Feb 14, 2013 and posted on Feb 11, 2013.
- Applicants must submit their applications by May 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Private institutions of higher education City or township governments For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts State governments Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Small businesses County governments Special district governments Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Institutes of Health (NIH) funding opportunity PAR 13-115, titled "Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R21)," supported exploratory and developmental projects intended to strengthen the scientific foundation for stem cell-based regenerative therapies. Using the R21 mechanism, the program emphasized early-stage, high-impact studies that could rapidly generate proof-of-concept data, new approaches, or enabling resources rather than long, fully mature research programs. The central idea was that better animal stem cell characterization and more predictive animal disease models would reduce uncertainty when translating regenerative medicine strategies toward human clinical use.
The research scope focused on three main themes. First, it encouraged comparative studies between animal and human stem cells to clarify similarities and differences that matter for translation. This includes work that helps researchers choose the most informative species or model system for a particular regenerative medicine question, especially where current models do not accurately reflect human biology, disease progression, or therapeutic response. Second, the FOA highlighted technology development for stem cell characterization and transplantation, meaning new or improved tools, methods, assays, imaging approaches, tracking strategies, or transplantation techniques that make it easier to analyze stem cell behavior, fate, integration, function, and safety in vivo. Third, it prioritized improving existing animal models and creating new ones that better capture human disease conditions in ways relevant to stem cell-based interventions, including models that allow more realistic testing of engraftment, tissue repair, functional recovery, immune interactions, and longer-term outcomes.
This opportunity was categorized as a discretionary grant program with a health research focus and was associated with multiple CFDA program areas, including oral diseases and disorders research (93.121), research infrastructure programs (93.351), cardiovascular diseases research (93.837), and arthritis, musculoskeletal, and skin diseases research (93.846). No cost sharing or matching was required, lowering barriers for applicants proposing method development or model-building work that can be difficult to fund through more traditional mechanisms.
The award structure included an award ceiling of $200,000, consistent with an R21-style exploratory budget cap. The FOA was posted on February 11, 2013, created on February 14, 2013, and remained open through a final closing date of May 7, 2016, after which it was archived on June 7, 2016. As a result, it served as a time-limited window for proposing new model systems and translationally focused stem cell research tools aligned with NIH priorities during that period.
Eligibility was broad and included a wide range of domestic and international organizations. Eligible applicants covered private and public institutions of higher education, nonprofit organizations (including 501(c)(3) and non-501(c)(3) entities), for-profit organizations (including small businesses and other for-profits), and various government entities such as city or township governments, county governments, state governments, special district governments, and tribal governments. The eligibility language also explicitly included many institution types and communities NIH often aims to reach, such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations where appropriate. Importantly, non-U.S. entities and foreign institutions were eligible to apply, and foreign components of U.S. organizations were allowed as defined by NIH policy.
Operationally, NIH served as the sponsoring agency, and the full announcement and policy details were provided via the NIH Grants Guide webpage listed in the opportunity. For technical access issues or linking problems, the NIH Office of Extramural Research (OER) webmaster contact was provided. Overall, PAR 13-115 was designed to push the field toward animal models and stem cell methodologies that more reliably predict human outcomes, ultimately helping regenerative medicine move from promising lab findings to therapies that can be tested and used with greater confidence.
Frequently Asked Questions (FAQ)
What is PAR 13-115?
PAR 13-115 is a National Institutes of Health (NIH) funding opportunity announcement titled "Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R21)." It supported exploratory and developmental research projects aimed at improving animal models and related methods used in stem cell-based regenerative medicine.
What is the main purpose of this funding opportunity?
The main purpose was to strengthen the scientific foundation for stem cell-based regenerative therapies by improving animal stem cell characterization and developing more predictive animal disease models. The overall intent was to reduce uncertainty when translating regenerative medicine strategies toward human clinical use.
What grant mechanism does this opportunity use?
This opportunity used the NIH R21 mechanism, which is intended for exploratory and developmental research.
What kinds of projects were emphasized under the R21 approach?
The program emphasized early-stage, high-impact studies that could rapidly generate proof-of-concept data, new approaches, or enabling resources, rather than long, fully mature research programs.
What research areas or themes were in scope for PAR 13-115?
The scope focused on three main themes: (1) comparative studies between animal and human stem cells to clarify translation-relevant similarities and differences; (2) technology development for stem cell characterization and transplantation (tools, methods, assays, imaging, tracking, and transplantation techniques); and (3) improving existing animal models or creating new ones that better capture human disease conditions relevant to stem cell-based interventions.
What is meant by comparative studies between animal and human stem cells?
Comparative studies were encouraged to clarify how animal stem cells and human stem cells are similar or different in ways that matter for translation to humans. This includes work that helps researchers select the most informative species or model system for a specific regenerative medicine question, especially when existing models do not reflect human biology, disease progression, or therapeutic response.
What types of technology development were highlighted?
The FOA highlighted developing or improving tools, methods, assays, imaging approaches, tracking strategies, and transplantation techniques that make it easier to analyze stem cell behavior, fate, integration, function, and safety in vivo.
What kinds of animal model improvements were prioritized?
It prioritized improving existing animal models and creating new ones that better represent human disease conditions in ways relevant to stem cell-based interventions. Examples of model capabilities mentioned include more realistic testing of engraftment, tissue repair, functional recovery, immune interactions, and longer-term outcomes.
How does this program relate to moving regenerative medicine toward human clinical use?
By promoting better animal stem cell characterization and more predictive disease models, the program aimed to make preclinical findings more reliable for predicting human outcomes, reducing uncertainty before clinical testing.
What is the funding category for this opportunity?
It was categorized as a discretionary grant program with a health research focus.
Which CFDA program areas were associated with PAR 13-115?
The opportunity was associated with multiple CFDA program areas, including oral diseases and disorders research (93.121), research infrastructure programs (93.351), cardiovascular diseases research (93.837), and arthritis, musculoskeletal, and skin diseases research (93.846).
Was cost sharing or matching required?
No. The opportunity stated that no cost sharing or matching was required.
What was the award ceiling?
The award ceiling was $200,000, consistent with an R21-style exploratory budget cap.
When was the FOA posted and when did it close?
The FOA was posted on February 11, 2013, created on February 14, 2013, and remained open until the final closing date of May 7, 2016. It was archived on June 7, 2016.
Is PAR 13-115 still open for applications?
No. Based on the provided dates, the opportunity reached its final closing date on May 7, 2016 and was archived on June 7, 2016.
Who was the sponsoring agency?
The sponsoring agency was the National Institutes of Health (NIH).
Where were the full announcement and policy details provided?
The full announcement and policy details were provided via the NIH Grants Guide webpage listed in the opportunity.
What types of organizations were eligible to apply?
Eligibility was broad and included domestic and international organizations. Eligible applicants included private and public institutions of higher education; nonprofit organizations (including 501(c)(3) and non-501(c)(3) entities); for-profit organizations (including small businesses and other for-profits); and government entities such as city or township governments, county governments, state governments, special district governments, and tribal governments.
Were minority-serving institutions specifically included in eligibility?
Yes. The eligibility language explicitly included institution types and communities such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Could faith-based or community-based organizations apply?
Yes. The eligibility description explicitly included faith-based or community-based organizations where appropriate.
Were non-U.S. entities or foreign institutions eligible?
Yes. Non-U.S. entities and foreign institutions were eligible to apply.
Were foreign components of U.S. organizations allowed?
Yes. Foreign components of U.S. organizations were allowed as defined by NIH policy.
What kind of support was mentioned for technical access issues?
For technical access issues or linking problems, a contact for the NIH Office of Extramural Research (OER) webmaster was provided in the opportunity information.
Browse more opportunities from the same category: Health
Next opportunity: FY 2013 OIA Brown Treesnake Program
Previous opportunity: Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 115
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 115) also looked into and applied for these:
| Funding Opportunity |
|---|
| Enhancing Opioid Treatment Program Patient Continuity of Care through Data Interoperability Apply for TI 13 010 Funding Number: TI 13 010 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $50,000 |
| NINDS Institutional Center Core Grants to Support Neuroscience Research (P30) Apply for PAR 13 116 Funding Number: PAR 13 116 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| STD Surveillance Network (SSuN) Apply for CDC RFA PS13 1306 Funding Number: CDC RFA PS13 1306 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,100,000 |
| Revision Applications for Research on Assessing the Role of Stigma in HIV Prevention and Care (R34) Apply for RFA MH 14 141 Funding Number: RFA MH 14 141 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Revision Applications for Research on Assessing the Role of Stigma in HIV Prevention and Care (R01) Apply for RFA MH 14 140 Funding Number: RFA MH 14 140 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Electronic Data Methods (EDM) Forum Second Phase (U18) Apply for RFA HS 13 004 Funding Number: RFA HS 13 004 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Rapid Hepatitis C Virus Screening and Referral Apply for TI 13 009 Funding Number: TI 13 009 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $40,000 |
| Offender Reentry Program Apply for TI 13 007 Funding Number: TI 13 007 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $430,000 |
| Rural Health Information Technology (HIT) Workforce Program Apply for HRSA 13 251 Funding Number: HRSA 13 251 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| State Public Health Actions to Prevent and Control Diabetes, Heart Disease, Obesity and Associated Risk Factors and Promote School Health Apply for CDC RFA DP13 1305 Funding Number: CDC RFA DP13 1305 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $745,000 |
| Research on Alcohol and HIV/AIDS (R03) Apply for PA 13 120 Funding Number: PA 13 120 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Alcohol and HIV/AIDS (R01) Apply for PA 13 121 Funding Number: PA 13 121 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Alcohol and HIV/AIDS (R21) Apply for PA 13 122 Funding Number: PA 13 122 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Limited Competition Extramural Research Facilities Improvement Program (C06) Apply for RFA OD 13 003 Funding Number: RFA OD 13 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Regional and International Differences in Health and Longevity at Older Ages (R03) Apply for PA 13 123 Funding Number: PA 13 123 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Regional and International Differences in Health and Longevity at Older Ages (R21) Apply for PA 13 124 Funding Number: PA 13 124 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Regional and International Differences in Health and Longevity at Older Ages (R01) Apply for PA 13 125 Funding Number: PA 13 125 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Stroke Trials Network Regional Coordinating Stroke Centers (U10) Apply for RFA NS 13 011 Funding Number: RFA NS 13 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Stroke Trials Network National Clinical Coordinating Center (U01) Apply for RFA NS 13 012 Funding Number: RFA NS 13 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| INNOVATE FOR HEALTH DRAFT APS Apply for 641 DRAFT 13 000001 Funding Number: 641 DRAFT 13 000001 Agency: Ghana USAID Accra Category: Health Funding Amount: $14,300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 115", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.